Cardiovascular Endocrinology & Metabolism最新文献_第10页

Pathogenesis and remission of type 2 diabetes: what has the twin cycle hypothesis taught us? 2 型糖尿病的发病机制和缓解：双循环假说给了我们什么启示？

IF 1.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-05-25 eCollection Date: 2020-12-01 DOI: 10.1097/XCE.0000000000000201

Ahmad Al-Mrabeh

引用次数: 0

Revisiting the pathogenic role of insulin resistance in Duchenne muscular dystrophy cardiomyopathy subphenotypes. 胰岛素抵抗在杜氏肌营养不良型心肌病亚表型中的致病作用。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-05-18 eCollection Date: 2020-12-01 DOI: 10.1097/XCE.0000000000000203

Antoine Fakhry AbdelMassih, Reem Esmail, Hanan Zekri, Ahmed Kharabish, Khaled ElKhashab, Rahma Menshawey, Habiba-Allah Ismail, Peter Afdal, Erini Farid, Omneya Affifi

{"title":"Revisiting the pathogenic role of insulin resistance in Duchenne muscular dystrophy cardiomyopathy subphenotypes.","authors":"Antoine Fakhry AbdelMassih, Reem Esmail, Hanan Zekri, Ahmed Kharabish, Khaled ElKhashab, Rahma Menshawey, Habiba-Allah Ismail, Peter Afdal, Erini Farid, Omneya Affifi","doi":"10.1097/XCE.0000000000000203","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000203","url":null,"abstract":"Introduction: Duchenne muscular dystrophy (DMD) is known to impact the subepicardial layer of the myocardium through chronic inflammation. Recent animal studies have shown predominant subendocardial involvement in rats with DMD. The primary outcome parameter was to determine by cardiovascular MRI (CMR) if two differential patterns of myocardial involvements exist in DMD; the secondary outcome parameters were to correlate the observed pattern with metabolic markers such as insulin resistance measures.Methods: Forty patients with DMD were screened using CMR to determine which of them had predominantly subendocardial dysfunction (SENDO group), or subepicardial/midmyocardial involvement (SEPMI group). Patients were subjected to body mass index measurement, serum creatinine kinase, serum lactate dehydrogenase enzyme, fasting glucose-insulin ratio (FGIR), full lipid profile, left ventricular ejection fraction (LVEF), left ventricle E/E´ ratio (the ratio of early mitral inflow velocity to average early diastolic velocities of the basal septum and mitral annulus) for left ventricle diastolic function, and myocardial layer strain discriminating echocardiography (MLSD-STE). Results: 26 patients displayed SENDO while 34 displayed SEPMI. SENDO group displayed overt insulin resistance; (FGIR (SENDO: 7 ± 1 vs. SEPMI: 5 ± 1, P < 0.001). FGIR was negatively correlated with Subendocardial Global Longitudinal Strain (ENDO-LS) with r = -0.75.Conclusion: DMD does not seem to influence the heart uniformly; DMD cardiomyopathy probably has two separate phenotypes with different mechanisms. Insulin resistance might be implicated in its pathogenesis and its reversal may help to slow disease progression.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"9 4","pages":"165-170"},"PeriodicalIF":2.3,"publicationDate":"2020-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000203","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38641605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Preventive cardiology or cardiometabolic medicine: a new and emerging subspecialty? 预防心脏病学还是心脏代谢医学:一个新兴的亚专科?

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-05-18 eCollection Date: 2020-09-01 DOI: 10.1097/XCE.0000000000000206

Nathan D Wong

{"title":"Preventive cardiology or cardiometabolic medicine: a new and emerging subspecialty?","authors":"Nathan D Wong","doi":"10.1097/XCE.0000000000000206","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000206","url":null,"abstract":"While we have seen great reductions in cardiovascular disease (CVD) morbidity and mortality over the past few decades, the rate of these declines has recently diminished, and there is even evidence that CVD mortality may be on the rise once again [1]. Much of this is fueled by the epidemic of obesity, metabolic syndrome and type 2 diabetes [2]. There is a wealth of evidence regarding the efficacy of cholesterol-lowering medications (particularly statins), blood pressure control, and most recently the treatment of diabetes with newer medications that positively impact CVD outcomes [2]. Yet recent data continue to demonstrate inadequate adherence to preventive medications and inadequate control of risk factors [3,4]. Even in the case of diabetes, where CVD is the major cause of morbidity and mortality, while many patients are at reasonable targets for HbA1c, blood pressure, and low-density lipoprotein-cholesterol individually, 20% or fewer are at all three targets simultaneously, suggesting a lack of coordinated care and understanding of the priorities that should be placed to reduce CVD risk in such persons [5]. Moreover, there is a continued rise in obesity both in developing and developed nations, with this closely linked to other cardiometabolic risk factors such as blood pressure and dyslipidemia, as well as being a strong determinant of type 2 diabetes. Consequently, there is an urgency for healthcare providers from different specialties to come together to address together the CVD risks common in many patients if we are to reduce, or at least prevent an imminent rise in CVD morbidity and mortality moving forward. While clearly there has been great progress made in the treatment of persons with known CVD, if we are to make further progress in the next few decades, there needs to be a shift in focus in cardiovascular medicine towards promoting cardiovascular health and prevention. A specialized field of preventive cardiology or cardiometabolic medicine [2] is meant to address this need.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"9 3","pages":"66-69"},"PeriodicalIF":2.3,"publicationDate":"2020-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000206","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38279791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications. 美国伴有心血管疾病的2型糖尿病患者心脏病科与内分泌科就诊的相对频率:对实施循证降糖药物的影响

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-05-15 eCollection Date: 2020-06-01 DOI: 10.1097/XCE.0000000000000195

Felona Gunawan, Michael E Nassif, Caitlin Partridge, Tariq Ahmad, Mikhail Kosiborod, Silvio E Inzucchi

{"title":"Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications.","authors":"Felona Gunawan, Michael E Nassif, Caitlin Partridge, Tariq Ahmad, Mikhail Kosiborod, Silvio E Inzucchi","doi":"10.1097/XCE.0000000000000195","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000195","url":null,"abstract":"Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in type 2 diabetes (T2D) patients. Recent cardiovascular outcome trials demonstrated clear cardiovascular benefits of novel classes of glucose-lowering agents. We performed retrospective electronic health record review at two major healthcare systems in the USA to determine the relative frequencies of outpatient encounters (hence prescribing opportunities) that a patient with T2D and CVD had with a cardiologist vs. an endocrinologist over one-year period. Of 109 747 T2D patients, 42.6% had established CVD. The ratio of cardiology-to-endocrinology outpatient encounters was 2.0:1 for all T2D patients, and 4.1:1 for those with T2D and CVD. Because each outpatient encounter provides an opportunity to discuss glucose-lowering medications with cardiovascular benefits, the much greater frequency of cardiology encounters highlights the emerging potential for cardiovascular specialists to influence or even implement evidence-based glucose-lowering therapies, thereby improving cardiovascular outcomes in their T2D patients.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"9 2","pages":"56-59"},"PeriodicalIF":2.3,"publicationDate":"2020-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000195","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38044013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20

Associations of adiponectin and leptin with brain natriuretic peptide in African Americans: the Jackson Heart Study. 非裔美国人的脂联素和瘦素与脑利钠肽的关系:杰克逊心脏研究。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-05-15 eCollection Date: 2020-06-01 DOI: 10.1097/XCE.0000000000000198

Steven R Horbal, Michael E Hall, Paul C Dinh, Abbas Smiley, Solomon K Musani, Jiankang Liu, Herman A Taylor, Ervin R Fox, Aurelian Bidulescu

{"title":"Associations of adiponectin and leptin with brain natriuretic peptide in African Americans: the Jackson Heart Study.","authors":"Steven R Horbal, Michael E Hall, Paul C Dinh, Abbas Smiley, Solomon K Musani, Jiankang Liu, Herman A Taylor, Ervin R Fox, Aurelian Bidulescu","doi":"10.1097/XCE.0000000000000198","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000198","url":null,"abstract":"Brain natriuretic peptide (BNP) is elevated in decompensated systolic and diastolic heart failure. The plasma levels of adipokines, such as adiponectin and leptin, may provide evidence for mechanistic differences in BNP concentrations. African-American-specific associations are limited in the literature. The objective of this study was to evaluate the associations of adiponectin and leptin with BNP among African Americans.Methods: Linear and logistic regressions were used to test the associations between adiponectin, leptin, and plasma BNP in 3738 participants of the Jackson Heart Study (JHS), a single-site prospective cohort study of African Americans in Jackson, Mississippi.Results: A direct relationship of adiponectin was observed in multiple multivariate-adjusted linear models: in men (β = 0.41-0.47), and in women (β = 0.32-0.38). Those in the highest quartile of adiponectin expression were twice as likely to have elevated BNP levels after adjustment [odds ratio 2.66 (95% confidence interval, 1.66-4.34)]. An inverse relationship of leptin with BNP was observed (β = -0.15) but attenuated after adjustment for aldosterone, renin, and adiponectin.Conclusions: Different linear associations of adiponectin and leptin with BNP were observed. Odds of elevated adiponectin were observed with elevated BNP in multivariate-adjusted models. This paradoxical relationship of adiponectin and plasma BNP is possibly explained through adiponectin resistance.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"9 2","pages":"49-55"},"PeriodicalIF":2.3,"publicationDate":"2020-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000198","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38044012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Clinical presentation of paroxysmal supraventricular tachycardia: evaluation of usual and unusual symptoms. 阵发性室上性心动过速的临床表现:通常和不寻常症状的评价。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-05-15 eCollection Date: 2020-12-01 DOI: 10.1097/XCE.0000000000000208

Ertan Yetkin, Selcuk Ozturk, Bilal Cuglan, Hasan Turhan

{"title":"Clinical presentation of paroxysmal supraventricular tachycardia: evaluation of usual and unusual symptoms.","authors":"Ertan Yetkin, Selcuk Ozturk, Bilal Cuglan, Hasan Turhan","doi":"10.1097/XCE.0000000000000208","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000208","url":null,"abstract":"Objective: Clinical presentation of paroxysmal supraventricular tachycardia may vary from asymptomatic occurrence or mild perception of palpitation to severe chest pain or syncope. This variation is the most challenging issue in the diagnostic evaluation of rhythm disturbances and paroxysmal supraventricular tachycardia as well. This study sought to evaluate the symptoms during the tachycardia attack or index event in patients who underwent electrophysiological study and ablation procedure.Methods: This retrospective study included 100 consecutive patients who underwent electrophysiological study and ablation procedures due to supraventricular tachycardia. Structural heart disease, moderate/severe valvular pathology, systemic pathologies, such as connective tissue disease and chronic obstructive lung disease, history of pacemaker implantation was defined as exclusion criteria. In addition, medically managed patients and patients with unsuccessful ablation were not included in the study.Results: Palpitation was the most frequently observed symptom in 84% of patients, followed by chest pain in 47%, dyspnea in 38%, syncope 26%, lightheadedness in 19%, and sweating in 18% of the patients. The most common symptoms after tachycardia event were fatigue and lightheadedness with frequencies of 56% and 55%, respectively. Forty-five percent of the patients reported more than one, unusually frequent urination within the following 1-3 hours after the index event.Conclusions: Paroxysmal supraventricular tachycardia might manifest itself as gastrointestinal, neurological, psychosomatic symptoms, and unusual complaints in association with or without main symptoms, including palpitation, chest pain, syncope, and dyspnea. Symptoms after tachycardia or index event should be questioned systematically.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"9 4","pages":"153-158"},"PeriodicalIF":2.3,"publicationDate":"2020-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673777/pdf/xce-9-153.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38641603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Sociodemographic and metabolic risk characteristics associated with metabolic weight categories in the Women's Health Initiative. 妇女健康倡议中与代谢体重类别相关的社会人口统计学和代谢风险特征。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-05-15 eCollection Date: 2020-06-01 DOI: 10.1097/XCE.0000000000000194

Amber R Cordola Hsu, Susan L Ames, Bin Xie, Darleen V Peterson, Lorena Garcia, Scott B Going, Nathan D Wong, Hoda Anton-Culver

{"title":"Sociodemographic and metabolic risk characteristics associated with metabolic weight categories in the Women's Health Initiative.","authors":"Amber R Cordola Hsu, Susan L Ames, Bin Xie, Darleen V Peterson, Lorena Garcia, Scott B Going, Nathan D Wong, Hoda Anton-Culver","doi":"10.1097/XCE.0000000000000194","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000194","url":null,"abstract":"To identify sociodemographic and metabolic correlates of weight categories in postmenopausal women.Methods: The Women's Health Initiative enrolled 161 808 postmenopausal women ages 50-79. We included those free of cardiovascular disease (CVD) and with CVD risk factors and biomarkers (n = 19 412). Normal weight was defined as a BMI ≥18.5 and <25 kg/m2 and waist circumference <88 cm and overweight/obesity as a BMI ≥25 kg/m2 or waist circumference ≥88 cm. Metabolically healthy was based on <2 and metabolically unhealthy ≥2 traits: triglycerides ≥150 mg/dl, systolic blood pressure (BP) ≥130 mmHg or diastolic BP ≥85 mmHg or antihypertensives or diuretics, fasting glucose ≥100 mg/dl or diabetes medication, and high-density lipoprotein cholesterol <50 mg/dl. Polytomous multinomial logistic regression with generalized link logit function provided the odds of metabolically healthy normal weight (MHNW), metabolically unhealthy normal weight (MUHNW), metabolically healthy overweight/obese (MHO), and metabolically unhealthy overweight/obese (MUHO) according to demographic and risk factor measures.Results: Among the 19 412 postmenopausal women, 2369 (12.2%) participants had prevalent diabetes. Advanced age was associated with an increased odds of MUHNW as compared with the MHNW after adjusting for covariates [odds ratio (OR) 1.04, P < 0.0001]. Black/African American ethnicity was associated with a decreased odds of MUHNW (OR 0.64, P < 0.0001) and MUHO (OR 0.77, P = 0.0004), while an increased odds for MHO (OR 1.50, P < 0.0001) as compared with White MHNW.Conclusions: Advanced age and ethnicity are important indicators of metabolic weight categories among postmenopausal women.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"9 2","pages":"42-48"},"PeriodicalIF":2.3,"publicationDate":"2020-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000194","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38044011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

A novel strategy to reduce the readmission rates in congestive heart failure: intermittent empirical intravenous diuretics. 减少充血性心力衰竭再入院率的新策略:间歇性经验性静脉利尿剂。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-05-15 eCollection Date: 2020-06-01 DOI: 10.1097/XCE.0000000000000200

Ertan Yetkin, Bilal Cuglan, Hasan Turhan, Selcuk Ozturk

{"title":"A novel strategy to reduce the readmission rates in congestive heart failure: intermittent empirical intravenous diuretics.","authors":"Ertan Yetkin, Bilal Cuglan, Hasan Turhan, Selcuk Ozturk","doi":"10.1097/XCE.0000000000000200","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000200","url":null,"abstract":"Improvements in the medical management of heart failure have changed the course of the disease. However, mortality rates, hospitalization rates, and treatment costs are not at desired levels. Diuretics have been widely used in the treatment of congestion in heart failure patients. The following case reports represent a special patient group treated and followed by cardiology clinic. Treatment approach of each case report has been tailored on an individual basis depending on the clinical course and hospitalization rates of patients. Authors have highlighted and discussed the common aspects and future perspectives of their cases in which post-discharge intermittent empirical intravenous diuretic administration dramatically improved the clinical status and readmission number due to decompensated congestive heart failure. This is a relatively new and promising approach, which has been thought to cease the recycle of diuretic resistance and silent increase of fluid congestion in patients with congestive heart failure and frequent hospitalization.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"9 2","pages":"60-63"},"PeriodicalIF":2.3,"publicationDate":"2020-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000200","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38043445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

A focused review of cardiovascular guideline related recommendations for the primary care physician in the USA. 针对美国初级保健医生的心血管指南相关建议的重点回顾。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-05-15 eCollection Date: 2020-06-01 DOI: 10.1097/XCE.0000000000000192

Omar Sheikh, Mouhamed Nashawi, Ayman Battisha, Robert Chilton

{"title":"A focused review of cardiovascular guideline related recommendations for the primary care physician in the USA.","authors":"Omar Sheikh, Mouhamed Nashawi, Ayman Battisha, Robert Chilton","doi":"10.1097/XCE.0000000000000192","DOIUrl":"10.1097/XCE.0000000000000192","url":null,"abstract":"Primary care physicians in the USA serve the critical role of first contact for undiagnosed or mismanaged pathologies as well as providers of continuous care in multiple communities. Their scope of practice is broad from medication reconciliation to coordinating specialty care and even performing office procedures. Primary care physicians in the USA commonly encounter patients with diabetes and associated comorbidities related to prolonged insulin resistance. Mainly these include heart failure exacerbation or major adverse cardiovascular events. The demanding roles primary care physicians serve may render these providers encumbered to navigate through long, verbose and dynamic guidelines related to managing diabetes and cardiac diabetology sequelae. Our aim is to compose current, prominent evidence-based points from American medical societies such as the American College of Cardiology/American Heart Association and the American Diabetes Association central to lifestyle modifications, antiplatelet therapy, anti-hyperglycemic and SGLT2-inhibitor utilization, hypertension, dyslipidemia, and heart failure screening in a way that is both succinct and valuable to primary care physicians.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"9 2","pages":"36-41"},"PeriodicalIF":2.3,"publicationDate":"2020-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228774/pdf/xce-9-36.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38044010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case model. 新型非他汀疗法对心血管糖尿病的系统性影响：以 PCSK9 为例

IF 1.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-05-05 eCollection Date: 2020-12-01 DOI: 10.1097/XCE.0000000000000204

Mouhamed Nashawi, Omar Sheikh, Mahnoor Mir, Tri Te, Robert Chilton

{"title":"The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case model.","authors":"Mouhamed Nashawi, Omar Sheikh, Mahnoor Mir, Tri Te, Robert Chilton","doi":"10.1097/XCE.0000000000000204","DOIUrl":"10.1097/XCE.0000000000000204","url":null,"abstract":"PCSK9, like other novel non-statin drugs were primarily developed to help patients achieve low-density lipoprotein cholesterol targets, especially in patients with dyslipidemia not achieving lipid goals with statins due to poor tolerance or inadequate response. PCSK9 inhibitors, in addition to modulating lipid metabolism, improve mortality outcomes in cardiovascular disease. These benefits are markedly pronounced in patients with type 2 diabetes mellitus. However, these benefits do not come without associated risk. Multiple trials, studies, and case reports have attempted to explain observed outcomes with PCSK9 expression and administration of PCSK9 inhibitors from multiple perspectives, such as their effects on insulin sensitivity and glucose tolerance, changes in renal physiology, thyroid physiology, vascular tone, intestinal regulation of lipids, and improved cardiovascular function. These agents represent an opportunity for physicians to exercise prudence by using appropriate clinical judgement when managing comorbidities in the hyperglycemic patient, a concept that extends to other novel non-statin drugs.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"9 4","pages":"143-152"},"PeriodicalIF":1.3,"publicationDate":"2020-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673769/pdf/xce-9-143.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38641602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0